Sam Brusco, Associate Editor12.15.23
Femasys began enrollment for its pivotal FemBloc trial at Stanford Medicine.
The FemBloc Intratubal Occlusion for Transcervical Permanent Birth Control (FINALE) trial will investigate safety and efficacy of the company’s investigational permanent birth control candidate. The trial targets the unmet need for women seeking permanent birth control for whom elective surgery is currently the only option.
“This trial could have significant implications to the health of women and all people who can become pregnant, and we are ready to commit Stanford’s resources and capabilities in research to continue to support the advancement of this important non-surgical option,” said Dr. Erica Cahill, MD.
“This continues to be an unprecedented time in women’s health and accessibility and preservation of options is crucial. An in-office birth control option has the opportunity to become an important solution healthcare providers can offer to their patients for their reproductive health needs on a non-surgical basis that also allows for broad accessibility”, added Dr. Paul Blumenthal, MD.
The company also provides FemaSeed, an FDA-cleared infertility treatment that is also approved in Canada. Femasys is also commercializing complementary diagnostics: FemVue, FemCath, and FemCerv. These were all made, according to the company, in its in-house R&D and manufacturing capabilities
“We are thrilled to include Stanford amongst the clinical trial sites participating in this initial phase of the FINALE trial, as we have partnered with Doctors Blumenthal and Cahill in earlier FemBloc studies,” said Femasys founder, president and CEO Kathy Lee-Sepsick. “Dr. Blumenthal, a leader in the field of gynecology, has dedicated his career to advancing research and bringing women’s health technologies to those in need around the globe. We greatly appreciate his long-standing support of FemBloc and the selection of Dr. Cahill as the principal investigator in the FINALE trial, as we continue to work together to progress this much needed non-surgical permanent birth control option for women."
Check out an episode of editor-in-chief Sean Fenske’s "Medtech Matters" podcast with Femasys founder and CEO Kathy Lee-Sepsick here!
The FemBloc Intratubal Occlusion for Transcervical Permanent Birth Control (FINALE) trial will investigate safety and efficacy of the company’s investigational permanent birth control candidate. The trial targets the unmet need for women seeking permanent birth control for whom elective surgery is currently the only option.
“This trial could have significant implications to the health of women and all people who can become pregnant, and we are ready to commit Stanford’s resources and capabilities in research to continue to support the advancement of this important non-surgical option,” said Dr. Erica Cahill, MD.
“This continues to be an unprecedented time in women’s health and accessibility and preservation of options is crucial. An in-office birth control option has the opportunity to become an important solution healthcare providers can offer to their patients for their reproductive health needs on a non-surgical basis that also allows for broad accessibility”, added Dr. Paul Blumenthal, MD.
The company also provides FemaSeed, an FDA-cleared infertility treatment that is also approved in Canada. Femasys is also commercializing complementary diagnostics: FemVue, FemCath, and FemCerv. These were all made, according to the company, in its in-house R&D and manufacturing capabilities
“We are thrilled to include Stanford amongst the clinical trial sites participating in this initial phase of the FINALE trial, as we have partnered with Doctors Blumenthal and Cahill in earlier FemBloc studies,” said Femasys founder, president and CEO Kathy Lee-Sepsick. “Dr. Blumenthal, a leader in the field of gynecology, has dedicated his career to advancing research and bringing women’s health technologies to those in need around the globe. We greatly appreciate his long-standing support of FemBloc and the selection of Dr. Cahill as the principal investigator in the FINALE trial, as we continue to work together to progress this much needed non-surgical permanent birth control option for women."
Check out an episode of editor-in-chief Sean Fenske’s "Medtech Matters" podcast with Femasys founder and CEO Kathy Lee-Sepsick here!